Figure 7.

Tumor-specific mtDNA mutations can be effectively detected in plasma samples based on optimized NGS approach

(A) Representative Venn diagrams of mtDNA variants detected by single-spot sequencing of matched tumor tissue, adjacent non-tumor tissue, PBMCs and plasma samples from HCC and CRC patients. (B) Representative Venn diagrams of mtDNA variants detected by multiple-spot sequencing of matched tumor tissue, adjacent non-tumor tissue, PBMCs, and plasma samples from HCC and CRC patients.